Matvieiev O. Monitoring of disease-modifying antirheumatic drugs safety in patients with juvenile idiopathic arthritis

A subject of dissertation is to increase safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, sulphasalazine, cyclosporine A, azathioprine and combination of methotrexate and glucocorticoids in patients with juvenile idiopathic arthritis (JIA) according to data of positive and negative effects monitoring. Density and remodelling of bone tissue (bone matrix synthesis and resorbtion), calcium and phosphorus metabolism, markers of inflammatory reaction (haptoglobin, C-reactive protein, seromucoid, leucocytes and ESR ) in correlation with pharmacotherapy parameters (drug dose and duration of therapy) were studied in 153 patients. We found dependence of density and remodelling processes on pharmacotherapy duration. Stature, weight and body mass index (BMI) correlated with inflammatory markers, bone density, osteocalcin and deoxypiridinoline concentrations. DMARDs except methotrexate and sulphasalazine influence on corellation and increase risk of osteopenia, growth, weight and BMI retardation.